Hepatocellular carcinoma screening: Difference between revisions
| Line 5: | Line 5: | ||
According to the American Association of Liver Diseases, [[Screening (medicine)|screening]] for hepatocellular carcinoma by [[ultrasound]] (US) is recommended among patients with [[hepatitis B]], [[hepatitis C]], and [[cirrhosis]]. [[Screening (medicine)|Screening]] is also recommended for Asian men over the age of 40, Asian women over the age of 50, and African American. | According to the American Association of Liver Diseases, [[Screening (medicine)|screening]] for hepatocellular carcinoma by [[ultrasound]] (US) is recommended among patients with [[hepatitis B]], [[hepatitis C]], and [[cirrhosis]]. [[Screening (medicine)|Screening]] is also recommended for Asian men over the age of 40, Asian women over the age of 50, and African American. | ||
==Screening== | ==Screening== | ||
[[Screening (medicine)|Screening]] for hepatocellular carcinoma by [[abdominal]] [[ultrasound]] and [[serum]] levels of [[alpha-fetoprotein]] is recommended for the following populations:<ref name="TradBibani2017">{{cite journal|last1=Trad|first1=Dorra|last2=Bibani|first2=Norsaf|last3=Sabbah|first3=Meriam|last4=Elloumi|first4=Hela|last5=Gargouri|first5=Dalila|last6=Ouakaa|first6=Asma|last7=Kharrat|first7=Jamel|title=Known, new and emerging risk factors of hepatocellular carcinoma (review)|journal=La Presse Médicale|volume=46|issue=11|year=2017|pages=1000–1007|issn=07554982|doi=10.1016/j.lpm.2017.09.025}}</ref> | [[Screening (medicine)|Screening]] for hepatocellular carcinoma by [[abdominal]] [[ultrasound]] and [[serum]] levels of [[alpha-fetoprotein]] is recommended for the following populations:<ref name="TradBibani2017">{{cite journal|last1=Trad|first1=Dorra|last2=Bibani|first2=Norsaf|last3=Sabbah|first3=Meriam|last4=Elloumi|first4=Hela|last5=Gargouri|first5=Dalila|last6=Ouakaa|first6=Asma|last7=Kharrat|first7=Jamel|title=Known, new and emerging risk factors of hepatocellular carcinoma (review)|journal=La Presse Médicale|volume=46|issue=11|year=2017|pages=1000–1007|issn=07554982|doi=10.1016/j.lpm.2017.09.025}}</ref><ref name="pmid29318354">{{cite journal |vauthors=Sirlin CB, Kielar AZ, Tang A, Bashir MR |title=LI-RADS: a glimpse into the future |journal=Abdom Radiol (NY) |volume=43 |issue=1 |pages=231–236 |year=2018 |pmid=29318354 |doi=10.1007/s00261-017-1448-1 |url=}}</ref> | ||
*Patients with [[hepatitis B]] | *Patients with [[hepatitis B]] | ||
*Patients with [[hepatitis C]] | *Patients with [[hepatitis C]] | ||
Revision as of 17:01, 23 January 2018
|
Hepatocellular carcinoma Microchapters |
|
Differentiating Hepatocellular carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hepatocellular carcinoma screening On the Web |
|
American Roentgen Ray Society Images of Hepatocellular carcinoma screening |
|
Risk calculators and risk factors for Hepatocellular carcinoma screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
According to the American Association of Liver Diseases, screening for hepatocellular carcinoma by ultrasound (US) is recommended among patients with hepatitis B, hepatitis C, and cirrhosis. Screening is also recommended for Asian men over the age of 40, Asian women over the age of 50, and African American.
Screening
Screening for hepatocellular carcinoma by abdominal ultrasound and serum levels of alpha-fetoprotein is recommended for the following populations:[1][2]
- Patients with hepatitis B
- Patients with hepatitis C
- Patietns with cirrhosis
- Asian men over the age of 40
- Asian women over the age of 50
- African American
References
- ↑ Trad, Dorra; Bibani, Norsaf; Sabbah, Meriam; Elloumi, Hela; Gargouri, Dalila; Ouakaa, Asma; Kharrat, Jamel (2017). "Known, new and emerging risk factors of hepatocellular carcinoma (review)". La Presse Médicale. 46 (11): 1000–1007. doi:10.1016/j.lpm.2017.09.025. ISSN 0755-4982.
- ↑ Sirlin CB, Kielar AZ, Tang A, Bashir MR (2018). "LI-RADS: a glimpse into the future". Abdom Radiol (NY). 43 (1): 231–236. doi:10.1007/s00261-017-1448-1. PMID 29318354.